Cytokinetics (CYTK) has entered into a royalty financing deal with Royalty Pharma, selling a share of its heart drug for up to $575 million. This move has lowered market expectations of an imminent buyout. Wall Street hopes dimmed as the company is also planning to revive omecamtiv with a new confirmatory Phase III trial. Additionally, Cytokinetics is expected to soon launch a promising new heart therapy called aficamten.
On Wall Street, hopes dimmed that Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, will be acquired. https://t.co/amHxGEO910
Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout https://t.co/XX5UJYrJcl via @elaineywchen and @matthewherper for @statnews
Maybe the most surprising thing about the $CYTK royalty financing deal and follow-on offering is not that Cytokinetics is not being imminently acquired but that the company is reviving omecamtiv with a new confirmatory Phase III trial. https://t.co/5J1Y1NE6G4
Cytokinetics $CYTK sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout https://t.co/3pzG81TniM via @matthewherper @elaineywchen
$CYTK Good. https://t.co/PFvngFEo9G
$CYTK offering
$CYTK Guess no buyout soon! https://t.co/BwkHp42WOb
I don’t often ask - but any pharma + biotech followers out there can help with $CYTK ? Near term (3-6m) views